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Background
The prognosis of Adult T-cell leukemia/lymphoma
(ATLL) associated with HTLV1 is dismal. The response
to conventional chemotherapy ranges between 20 and
70% and relaspe is constant. Median survival is 8 to 13
months. Chronic and smouldering ATLL have a longer
survival, ranging from 18 to 72 months at 5 years. Inter-
feron alpha (IFNa) and AZT combination therapy is
effective in acute, chronic and smouldering ATLL,
sometimes leading to complete response and has a bet-
ter prognosis than conventional chemotherapy (5 year
survival of 82% in acute and 100% in chronic and
smouldering forms reaching a complete response).
Patients with ATLL/lymphoma do not benefit from
IFNa+AZT combination and despite initial response to
chemotherapy, all patients eventually relapse. Arsenic
trioxyde (AsO3) in combination with IFNa has in vitro
activity with a negative regulation of the Tax oncopro-
tein and leads to apoptosis of HTLV1 transformed lym-
phocytes. A recent study has showed a benefit in
chronic forms of ATLL.
Patients and methods
11 patients with ATLL were treated with AsO3+IFN
combination after a minimum of 1 line of treatment.
Results
3 patients had ATLL/lymphoma, 3 chronic and 5 acute.
All patients had recieved previous therapy with
chemotherapy associated or not with IFNa/AZT combi-
nation. At initiation of AsO3, 4 patients were in com-
plete response (3 lymphoma, 1 acute), 2 partial response
(1 acute, 1 chronic) et 5 in progression (3 acute, 2
chronic). 10 patients recieved AsO3 during 3 to 8 weeks
1 patient progressed 3 days after starting AsO3. Toler-
ance was acceptable with peripheral neurolopathy (n =
4), hand and foot syndrome (n = 3) et drug eruption
(n = 3 including 2 toxic epidermal necrolysis). 6 patients
died, and all were progressing at time of AsO3 initia-
tion. 5 patients survived : 3 lymphomas in complete
response (25, 31 et 46 months follow-up), 1 acute in
complete response (9 months follow-up) and 1 one
chronic in partial response (39 months follow-up).
Conclusion
AsO3 and IFNa combination has an acceptable toler-
ance profile and seems to be effective in ATLL in con-
solidation after response to a previous treatment,
particularly in lymphoma and chronic forms.
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